Recombinant Human Ly6D Fc Chimera Protein, CF Summary
Accession # Q14210
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.|
|Reconstitution||Reconstitute at 200 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
2 μg/lane of Recombinant Human Ly6D Fc Chimera (Catlog # 10169-L6) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 38-46 kDa and 80-90 kDa, respectively.
Recombinant Human Ly6D Fc Chimera (Catalog # 10169-L6) inhibits anti-CD3 antibody induced IFN-gamma secretion by human T cells. The ED50 for this effect is 1-7.5 μg/mL.
Ly6D (Lymphocyte antigen 6D), also known as E48 antigen, is a member of the lymphostromal cell membrane Ly6 protein superfamily (1, 2). There are at least twenty different human Ly6 proteins that have been identified, ranging from 11 to 36 kDa. These are classified as either secreted, or membrane-bound proteins which have the GPI-anchor signaling sequence. Included in the GPI-anchored cell surface glycoproteins are Ly6A-I and Ly6K (2-4). Human Ly6D is synthesized as a 128 amino acid (aa) protein that includes a 20 aa signal peptide, a 78 aa Ly6D chain, and a 30 aa propeptide. Within the main chain region, human Ly6D shares 64% and 58% aa sequence identity with mouse and rat Ly6D, respectively. Ly6D expression is significantly increased in bladder, brain and CNS, breast, head and neck, gastric, lung, ovarian, pancreatic, colorectal and kidney cancer than their counterpart normal tissues. High Ly6D expression is correlated with poor clinical outcome in brain and CNS, pancreatic, and colorectal, breast, colorectal, lung, gastric and ovarian cancer (4). LY6D is a progenitor marker that liaises intrinsically castration-resistant luminal cells and castration-resistant prostate tumor growth (5). LY6D is associated with an aggressive phenotype of ER-positive breast carcinoma, and these are potent markers for distant metastasis of ER-positive breast cancer patients (6).
- Gumley, T.P. et al. (1995) Immunol. Cell Biol. 73:277.
- Lv, Y. et al. (2018) Cell. Physiol. Biochem. 45:1219.
- Kong, H.K. and J.H. Park. (2012) BMB Rep. 45:595.
- Luo, L. et al. (2016) Oncotarget 7:11165.
- Barros-Silva JD, et al. (2018) Cell Rep. 25:3504
- Mayama A et al. (2018) Cancer Sci. 109:3350.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human Ly6D Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human Ly6D Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Human Ly6D Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image